U.S., Sept. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07182721) titled 'SKB264 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Progressing After T-DXd Treatment' on Sept. 13.
Brief Summary: This is a prospective, single-arm, single-center, Phase II clinical study designed to assess the preliminary efficacy and safety of SKB264 Plus Inetetamab plus inetetamab for the treatment of HER2-positive, unresectable, locally advanced or metastatic breast cancer following progression on prior T-DXd therapy.
Study Start Date: Sept. 30
Study Type: INTERVENTIONAL
Condition:
HER2-positive, Unresectable, Locally Advanced or Metastatic Breast Cancer
SKB264
Inetetamab
Intervention:
DRUG: SKB264 ...